BR112018075475A2 - uso de vitamina a e/ou equivalentes funcionais, vitamina d e/ou equivalentes funcionais e pelo menos um pufa ômega-3, método para tratar, reduzir e/ou prevenir neuroinflamação, composição para uso terapêutico no tratamento, redução e/ou prevenção de neuroinflamação e combinação de vitamina a e/ou equivalentes funcionais, vitamina d e/ou equivalentes funcionais e pelo menos um pufa ômega-3 - Google Patents

uso de vitamina a e/ou equivalentes funcionais, vitamina d e/ou equivalentes funcionais e pelo menos um pufa ômega-3, método para tratar, reduzir e/ou prevenir neuroinflamação, composição para uso terapêutico no tratamento, redução e/ou prevenção de neuroinflamação e combinação de vitamina a e/ou equivalentes funcionais, vitamina d e/ou equivalentes funcionais e pelo menos um pufa ômega-3

Info

Publication number
BR112018075475A2
BR112018075475A2 BR112018075475A BR112018075475A BR112018075475A2 BR 112018075475 A2 BR112018075475 A2 BR 112018075475A2 BR 112018075475 A BR112018075475 A BR 112018075475A BR 112018075475 A BR112018075475 A BR 112018075475A BR 112018075475 A2 BR112018075475 A2 BR 112018075475A2
Authority
BR
Brazil
Prior art keywords
vitamin
functional equivalents
omega
neuroinflammation
treating
Prior art date
Application number
BR112018075475A
Other languages
English (en)
Inventor
Maarten Verkuijl Jan
Maria Broersen Ladislaus
Johan Joseph Hageman Robert
Lopes Da Silva Sofia
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56550947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018075475(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of BR112018075475A2 publication Critical patent/BR112018075475A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubrication Of Internal Combustion Engines (AREA)

Abstract

a invenção pertence ao uso de quantidades terapeuticamente efetivas de (i) vitamina a e/ou equivalentes funcionais, (ii) vitamina d e/ou equivalentes funcionais, e (iii) pelo menos um pufa ômega-3, preferencialmente dha e/ou epa, mais preferencialmente dha e epa, para a fabricação de uma composição ou medicamento para tratar, reduzir e/ou prevenir neuroinflação e/ou sintomas associados com neuroinflamação em um sujeito com necessidade do mesmo, bem como para reduzir ativação da microglia e/ou para tratar, reduzir e/ou prevenir sintomas associados com ativação excessiva da microglia e/ou reduzir a secreção de citocinas inflamatórias, preferencialmente il-6, e/ou para tratar, reduzir e/ou prevenir sintomas associados com secreção excessiva de citocinas inflamatórias, em um sujeito com necessidade do mesmo.
BR112018075475A 2016-06-10 2017-06-09 uso de vitamina a e/ou equivalentes funcionais, vitamina d e/ou equivalentes funcionais e pelo menos um pufa ômega-3, método para tratar, reduzir e/ou prevenir neuroinflamação, composição para uso terapêutico no tratamento, redução e/ou prevenção de neuroinflamação e combinação de vitamina a e/ou equivalentes funcionais, vitamina d e/ou equivalentes funcionais e pelo menos um pufa ômega-3 BR112018075475A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2016/050419 WO2017213490A1 (en) 2016-06-10 2016-06-10 Method for controlling neuroinflammation
PCT/NL2017/050380 WO2017213504A1 (en) 2016-06-10 2017-06-09 Method for controlling neuroinflammation

Publications (1)

Publication Number Publication Date
BR112018075475A2 true BR112018075475A2 (pt) 2019-03-19

Family

ID=56550947

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075475A BR112018075475A2 (pt) 2016-06-10 2017-06-09 uso de vitamina a e/ou equivalentes funcionais, vitamina d e/ou equivalentes funcionais e pelo menos um pufa ômega-3, método para tratar, reduzir e/ou prevenir neuroinflamação, composição para uso terapêutico no tratamento, redução e/ou prevenção de neuroinflamação e combinação de vitamina a e/ou equivalentes funcionais, vitamina d e/ou equivalentes funcionais e pelo menos um pufa ômega-3

Country Status (9)

Country Link
US (1) US10821120B2 (pt)
EP (1) EP3468543B1 (pt)
CN (1) CN109562081B (pt)
BR (1) BR112018075475A2 (pt)
ES (1) ES2966773T3 (pt)
FI (1) FI3468543T3 (pt)
PL (1) PL3468543T3 (pt)
PT (1) PT3468543T (pt)
WO (2) WO2017213490A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118796A1 (en) 2011-02-28 2012-09-07 The Schepens Eye Research Institute, Inc. Compositions for controlling neuronal outgrowth
US20230338305A1 (en) * 2020-05-06 2023-10-26 Regenall Limited Vitamin a for use in the treatment of traumatic brain injury
CN116139171B (zh) * 2021-11-22 2025-07-29 深圳奥萨制药有限公司 一种改善轻度脑认知功能障碍的组合物
EP4514348A4 (en) * 2022-04-29 2025-12-31 Noetix Pharma Llc PREVENTION AND TREATMENT OF POSTOPERATIVE COGNITIVE DYSFUNCTIONS (POCD)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704542B2 (en) 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
EP1800675B1 (en) 2005-12-23 2011-05-18 N.V. Nutricia Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
WO2007104030A1 (en) * 2006-03-08 2007-09-13 Kinemed, Inc. Retinoids and related compounds for the treatment of neuroinflammatory conditions, diseases and disorders
WO2009002148A1 (en) 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
CN101433240B (zh) * 2007-11-16 2013-01-16 光明乳业股份有限公司 一种适合孕妇和乳母食用的牛奶及其制备方法
US20120128711A1 (en) 2009-09-21 2012-05-24 Total Nutraceutical Solutions, Inc. Anti-inflammatory approach to prevention and suppression of post-traumatic stress disorder, traumatic brain injury, depression and associated disease states
CN102843920A (zh) * 2010-01-29 2012-12-26 N·V·努特里奇亚 适用于管饲的、使上消化道和下消化道病症最小化的液体肠营养组合物
EP2568826A4 (en) * 2010-05-13 2014-03-26 Nitromega Corp NITRATED FATTY ACIDS, NEUROPROTECTION AND / OR INHIBITION OF COGNITIVE DECLINE
WO2012125020A1 (en) 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
US20120252888A1 (en) 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
WO2013066151A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
WO2013066152A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
EP3174544B1 (en) * 2014-07-31 2020-12-09 Universita' Degli Studi Di Cagliari Ester of a phospholipid with conjugated linoleic acid for the treatment of psychiatric disorders with neuroinflammatory and neurodegenerative basis
WO2016072842A1 (en) * 2014-11-05 2016-05-12 N.V. Nutricia Method for preventing, reducing the risk of, or treating behavioral frontotemporal dementia

Also Published As

Publication number Publication date
PT3468543T (pt) 2023-12-14
US10821120B2 (en) 2020-11-03
ES2966773T3 (es) 2024-04-24
WO2017213504A1 (en) 2017-12-14
US20190175622A1 (en) 2019-06-13
EP3468543A1 (en) 2019-04-17
FI3468543T3 (fi) 2023-10-31
EP3468543B1 (en) 2023-10-04
WO2017213490A1 (en) 2017-12-14
CN109562081A (zh) 2019-04-02
CN109562081B (zh) 2022-03-18
PL3468543T3 (pl) 2024-03-18

Similar Documents

Publication Publication Date Title
ZA201903091B (en) Methods of treating inflammatory conditions
BR112017015310A8 (pt) uso de pgr4 como um agente anti-inflamatório
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX388385B (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
NZ722326A (en) Tricyclic compounds as anticancer agents
MX2017005875A (es) Metodos para tratar enfermedades oculares.
BR112018075475A2 (pt) uso de vitamina a e/ou equivalentes funcionais, vitamina d e/ou equivalentes funcionais e pelo menos um pufa ômega-3, método para tratar, reduzir e/ou prevenir neuroinflamação, composição para uso terapêutico no tratamento, redução e/ou prevenção de neuroinflamação e combinação de vitamina a e/ou equivalentes funcionais, vitamina d e/ou equivalentes funcionais e pelo menos um pufa ômega-3
MX2017016491A (es) Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).
MX2017011037A (es) Bacteria manejada geneticamente para tratar enfermedades que se benefician de inflamacion intestinal reducida y/o barrera mucosa intestinal fortalecida.
EA201991650A1 (ru) Способы лечения неврологических расстройств
CL2019000190A1 (es) Tratamiento y prevención de los trastornos del sueño.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
EA202092225A1 (ru) Соединения и их применение
MX373231B (es) Agente anticancerigeno.
CL2022003348A1 (es) Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
EP3411399A4 (en) TECHNOLOGY FOR ANTIBODY-ACTIVE SYNERGISM FOR THE TREATMENT OF DISEASES
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
HK1258762A1 (zh) Btk抑制剂gs-4059与选自jak、ask1、brd和/或mmp9抑制剂的抑制剂的组合，以治疗癌症、过敏性病症、自身免疫疾病或发炎性疾病
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
MA41114B1 (fr) Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]